Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 庄立信教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1002/1098-2388(200009)19:2<116::AID-SSU4>3.0.CO;2-F |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/15WOS source URL
其它资讯
摘要Primary and secondary liver tumors have a reputation for being resistant to chemotherapy and, in the absence of surgical resection, rapidly fatal. Until recently, such a reputation was well justified: response rates above 20% were not seen, and complete responses were distinctly rare. Over the past 5 years, the mood of those in the field has become rather more optimistic and a pattern of effective therapy is emerging. This involves combination therapy in patients with unresectable disease to increase the operative rates, and postoperative adjuvant therapy to decrease the high relapse rate which is so characteristic of both primary and secondary liver tumors. In the case of hepatocellular carcinoma, the combination therapy involves cytotoxic drugs and interferon. With secondary colorectal cancer (CRC), the combination of 5-fluorouracil (FU) and leucovorin, together with one of the new cytotoxic agents such as oxaliplatin or irenotecan, is producing much higher response rates and prolonged survival, and permitting a higher resection rate. Postoperative treatment is also showing promise in decreasing the relapse rate. With CRC metastatic to the liver, this involves hepatic artery infusion (HAI), systemic 5-FU, and leucovorin. Adjuvant systemic therapy of HCC has not yet been widely tested, but success with locoregional lipiodol iodine(131) is proof of principle. The coming decade should see a significant improvement in the outlook of patients with malignant liver tumors as multimodality treatment becomes more widely investigated and practiced. Semin. Surg. Oncol. 19:116-124, 2000. (C) 2000 Wiley-Liss, Inc.
着者Johnson PJ
期刊名称Seminars in Surgical Oncology
出版年份2000
月份9
日期1
卷号19
期次2
出版社WILEY-LISS
页次116 - 124
国际标準期刊号8756-0437
语言英式英语
关键词adjuvant chemotherapy; alpha-fetoproteins; carcinoid tumor; chronotherapy; colorectal neoplasms; combined antineoplastic agents; combined modality therapy; doxorubicin; fluorouracil; hepatocellular carcinoma; interferon alfa-2b; leucovorin; liver neoplasms; local neoplasm recurrence; neoplasm metastasis; prognosis; survival rate; tegafur
Web of Science 学科类别Oncology; Surgery
